BioCentury
ARTICLE | Product Development

Bilenker, Engelman launch Treeline with difficult-to-drug cancer targets as first focus

April 27, 2021 12:53 AM UTC

Josh Bilenker and Jeffrey Engelman have founded and secured a tranched series A round for Treeline to develop therapeutics, initially for cancer, using a toolbox stocked with emerging and established technologies. 

Bilenker, Treeline Biosciences Inc.’s CEO, co-founded Loxo Oncology Inc., which found early success with precision oncology drugs and was acquired by Eli Lilly and Co. (NYSE:LLY) in 2019. Bilenker stepped down as the Lilly unit’s CEO in January...